Division of Breast Services, Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
Ohio University Heritage College of Osteopathic Medicine, Athens, OH, USA.
Ann Surg Oncol. 2018 Oct;25(10):3052-3056. doi: 10.1245/s10434-018-6597-0. Epub 2018 Jul 2.
Autologous fat grafting (AFG) is utilized for cosmetic improvement of the reconstructed breast following mastectomy. Fat necrosis (FN), a benign complication of AFG, can raise suspicion of malignancy and require further evaluation.
The aim of this study was to determine the incidence of FN in patients who have undergone AFG following mastectomy and reconstruction, and to identify factors contributing to FN.
A retrospective chart review was conducted of all patients who received AFG following mastectomy and reconstruction at our institution between 2011 and 2016, with a minimum 6-month follow-up period. Patient information, operative details, receipt of radiation, complications, and incidence of cancer recurrence were collected.
A total of 171 patients were included in this study. AFG was performed by seven surgeons. Patients received an average of 1.18 treatments, with average follow-up of 26 months. Eighteen patients (10.5%) developed FN an average of 3.4 months following AFG. Patients with a larger volume injected at initial session (p = 0.044) and longer length of follow-up (p = 0.026) had significant increases in risk of developing FN. Core needle biopsy was performed in seven patients and two patients required excision. The rate of cancer recurrence was 1.7% for all patients and 0% in the AFG cohort.
Increased risk of FN following AFG is associated with greater volume injected at the initial session and higher incidence over time. Although AFG is oncologically safe, patients should be counseled on the 10.5% incidence of FN presenting as a palpable abnormality, and the approximately 5% chance of requiring biopsy or excision.
自体脂肪移植(AFG)用于乳房切除术后重建乳房的美容改善。脂肪坏死(FN)是 AFG 的良性并发症,可能会引起恶性肿瘤的怀疑,并需要进一步评估。
本研究旨在确定接受乳房切除和重建术后接受 AFG 的患者中 FN 的发生率,并确定导致 FN 的因素。
对 2011 年至 2016 年期间在我们机构接受乳房切除和重建术后接受 AFG 的所有患者进行回顾性图表审查,随访时间至少为 6 个月。收集患者信息、手术细节、放疗、并发症和癌症复发情况。
共有 171 名患者纳入本研究。AFG 由 7 名外科医生进行。患者平均接受 1.18 次治疗,平均随访 26 个月。18 名患者(10.5%)在 AFG 后平均 3.4 个月出现 FN。初始治疗时注射量较大的患者(p=0.044)和随访时间较长的患者(p=0.026)FN 风险显著增加。对 7 名患者进行了芯针活检,2 名患者需要切除。所有患者的癌症复发率为 1.7%,AFG 组为 0%。
AFG 后 FN 的风险增加与初始治疗时注射量较大和随时间推移发生率增加有关。尽管 AFG 在肿瘤学上是安全的,但应告知患者 10.5%的 FN 发生率表现为可触及的异常,以及大约 5%的患者需要活检或切除的风险。